Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment

Failure to Biktarvy® and development of resistance mutations in an antiretroviral-experienced patient

(2020) Ana Belén Lozano et al.   ANTIVIRAL RESEARCH

Increased age and male sex are independently associated with higher frequency of blood–cerebrospinal fluid barrier dysfunction using the albumin quotient

(2020) Massimiliano Castellazzi et al.   Fluids and Barriers of the CNS

Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation

(2020) Felix Stader et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Antiretroviral drug concentrations in brain tissue of adult decedents

(2020) Micol Ferrara et al.   AIDS

Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV

(2020) Andrea Calcagno et al.   CLINICAL PHARMACOKINETICS

Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries

(2020) Thibaut Gelé et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

No changes in HIV suppression and inflammatory markers in CSF in patients randomly switched to DTG + 3TC (Spanish HIV/AIDS Research Network, PreEC/RIS 62)

(2020) Juan M Tiraboschi et al.   JOURNAL OF INFECTIOUS DISEASES

Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species

(2019) Corbin G. Thompson et al.   Science Translational Medicine

Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1–Infected Patients with Central Nervous System Impairment

(2019) Thibaut Gelé et al.   Open Forum Infectious Diseases

Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid

(2019) Qing Ma et al.   CLINICAL INFECTIOUS DISEASES

Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56)

(2019) Juan Tiraboschi et al.   JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

(2019) Scott L Letendre et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

UPLC–MS/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma

(2019) Hélène Gouget et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

(2017) Joel E. Gallant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Mechanisms of CNS Viral Seeding by HIV + CD14 + CD16 + Monocytes: Establishment and Reseeding of Viral Reservoirs Contributing to HIV-Associated Neurocognitive Disorders

(2017) Mike Veenstra et al.   mBio

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

(2017) Adam Trickey et al.   Lancet HIV

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

(2016) Manuel Tsiang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Persistent HIV-1 replication maintains the tissue reservoir during therapy

(2016) Ramon Lorenzo-Redondo et al.   NATURE

HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment

(2016) Deanna Saylor et al.   Nature Reviews Neurology

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects

(2014) S. L. Letendre et al.   CLINICAL INFECTIOUS DISEASES

Protein-Free Efavirenz Concentrations in Cerebrospinal Fluid and Blood Plasma Are Equivalent: Applying the Law of Mass Action To Predict Protein-Free Drug Concentration

(2013) L. B. Avery et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

(2013) Peter J. Ruane et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Etravirine in CSF is highly protein bound

(2013) A. Nguyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340,In Vitro

(2012) Eve-Irene Lepist et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir

(2012) Brookie M. Best et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

(2012) D. Croteau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection

(2012) Victor Valcour et al.   JOURNAL OF INFECTIOUS DISEASES

Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage

(2011) Andrea Calcagno et al.   AIDS

Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants

(2011) Patricia M. Flynn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1

(2010) D. Croteau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System

(2008) Scott Letendre   ARCHIVES OF NEUROLOGY